Ascendis Pharma A/S (ASND)
253.38
+1.43
(+0.57%)
USD |
NASDAQ |
Aug 25, 16:00
253.38
0.00 (0.00%)
After-Hours: 17:16
Ascendis Pharma Debt to Equity Ratio : 0.3133 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.3133 |
| March 31, 2026 | 1.838 |
| December 31, 2025 | -5.354 |
| September 30, 2025 | -4.674 |
| June 30, 2025 | -4.225 |
| March 31, 2025 | -4.464 |
| December 31, 2024 | -8.104 |
| September 30, 2024 | -8.104 |
| June 30, 2024 | -2.095 |
| March 31, 2024 | -2.809 |
| December 31, 2023 | -4.422 |
| September 30, 2023 | -9.067 |
| June 30, 2023 | 7.803 |
| March 31, 2023 | 3.023 |
| December 31, 2022 | 1.930 |
| September 30, 2022 | 1.225 |
| June 30, 2022 | 0.8427 |
| March 31, 2022 | 0.704 |
| December 31, 2021 | 0.1188 |
| September 30, 2021 | 0.103 |
| June 30, 2021 | 0.1469 |
| March 31, 2021 | 0.1202 |
| December 31, 2020 | 0.1097 |
| September 30, 2020 | 0.035 |
| June 30, 2020 | 0.0744 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0675 |
| December 31, 2019 | 0.0613 |
| September 30, 2019 | 0.0559 |
| June 30, 2019 | 0.0538 |
| March 31, 2019 | 0.0244 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Evaxion AS | 0.7455 |
| Genmab A/S | 0.8852 |
| Zealand Pharma A/S | 0.0228 |
| Cellectis SA | 2.539 |
| BioMarin Pharmaceutical, Inc. | 0.6672 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.614B |
| Total Liabilities (Quarterly) | 971.27M |
| Shareholders Equity (Quarterly) | 1.642B |
| Current Ratio | 2.991 |
| Net Debt Paydown Yield | 0.46% |